Literature DB >> 17621383

The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study.

Helen Lavretsky1, Prabha Siddarth, Anand Kumar, Charles F Reynolds.   

Abstract

BACKGROUND: The authors examined the role of dopamine and serotonin transporter genetic polymorphisms in clinical and cognitive features of subjects with late-life depression, and in preferential treatment response to the combination of methylphenidate and citalopram.
METHOD: The authors studied fifteen outpatients with major depression in a pilot ten-week double-blind trial of methylphenidate combined with citalopram and compared to citalopram and placebo. Response was defined as a score on the Hamilton Depression Rating Scale (24-item) of less than 10. All underwent genotyping to determine the dopamine (DAT VNTR) and serotonin (5HTTLPR) transporter polymorphisms.
RESULTS: Subjects with DAT VNTR 10/10 genotype had greater cognitive executive dysfunction at baseline compared to others. However, they responded preferentially to methylphenidate added to citalopram with a greater reduction in depression severity over time compared to other subjects.
CONCLUSIONS: DAT VNTR 10/10 genotype may be associated with an endophenotype of late-life depression with executive dysfunction that responds preferentially to methylphenidate added to a selective serotonin reuptake inhibitor, which warrants replication in a large sample.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17621383     DOI: 10.1002/gps.1837

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  3 in total

1.  Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.

Authors:  Harris A Eyre; Ascia Eskin; Stanley F Nelson; Natalie M St Cyr; Prabha Siddarth; Bernhard T Baune; Helen Lavretsky
Journal:  Int J Geriatr Psychiatry       Date:  2015-10-15       Impact factor: 3.485

Review 2.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

3.  Pharmacogenetics of antidepressants.

Authors:  Concetta Crisafulli; Chiara Fabbri; Stefano Porcelli; Antonio Drago; Edoardo Spina; Diana De Ronchi; Alessandro Serretti
Journal:  Front Pharmacol       Date:  2011-02-16       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.